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مسية األفالتوكسني يف اخلاليا البشرية اللمفاوية 
�صليمان �حلمادي, فريدة �ملرزوقي, عائ�صة �ملن�صوري, �ألن �صاهي, مرمي �ل�صم�صي, �إريك من�صه بر�ون, عبد �لقادر �صويد
abstract: Objectives: Aflatoxin B1 (AFB1) is a naturally occurring carcinogenic and immunosuppressive 
compound. This study was designed to measure its toxic effects on human peripheral blood mononuclear cells 
(PBMC). Methods: The study recruited 7 healthy volunteers. PBMC were isolated and cellular respiration was 
monitored using a phosphorescence oxygen analyser. The intracellular caspase activity was measured by the 
caspase-3 substrate N-acetyl-asp-glu-val-asp-7-amino-4-methylcoumarin. Phosphatidylserine exposure and 
membrane permeability to propidium iodide (PI) were measured by flow cytometry. Results: Cellular oxygen 
consumption was inhibited by 2.5 µM and 25 µM of AFB1. Intracellular caspase activity was noted after two 
hours of incubation with 100 µM of AFB1. The number of Annexin V-positive cells increased as a function of 
AFB1 concentration and incubation time. At 50 µM, a significant number of cells became necrotic after 24 hours 
(Annexin V-positive and PI-positive). Conclusion: The results show AFB1 is toxic to human lymphocytes and that 
its cytotoxicity is mediated by apoptosis and necrosis.
Keywords: Aflatoxin B1; Oxygen Analyzer; Cellular Respiration; Mitochondria; Caspases; Leukocytes, Mononuclear.
امللخ�ص: الهدف: �الأفالتوك�صي هو مركب طبيعي م�صبب لل�رشطان ولنق�س �ملناعة. هذه �لدر��صة تقّيم �الآثار �ل�صامة لالأفالتوك�صي على �خلاليا �لب�رشية 
�للمفاوية. متت هذه �لدر��صة بي ت�رشين ثاين 2008 وحزير�ن 2012. الطريقة: عزلت خاليا دموية ملفاوية من �صبعة متطوعي �أ�صحاء. ر�صد �لتنف�س 
�خللوي بو��صطة �ملوؤ�رش �لف�صفوري لك�صف �الأك�صجي. وك�صف ن�صاط �نزمي �لكا�صبي�س د�خل �خللية با�صتخد�م �ملادة �لف�صفورية �مل�صتقة من كومارين �لقادرة 
�يود�يد  لربوبدمي  �خللية  غ�صاء  نفاذية  زيادة  و  �صريين  �لفو�صفاتيديل  ملادة  �لتعر�س  قيا�س  طريق  عن  �خللية  موت  قيا�س  مت  �الإنزمي.  ن�صاط  قيا�س  على 
با�صتخد�م تقنية �لتدفق �خللوي. النتائج: �الأفالتوك�صي )μM 2.5 و μM 25( ثبط �ال�صتهالك �خللوي لالأك�صجي. ظهرت فعالية �لكا�صبي�س د�خل �خلاليا 
بعد �صاعتي من �إ�صافة �الأفالتوك�صي. عدد �خلاليا �مليتة �اليجابية ملادة �النيكزن-V �رتفع بزيادة جرعة �الأفالتوك�صي وبزيادة زمن تعر�س �خلاليا لهذ� 
�ل�صم. عند �إ�صافة μM 50 من �الأفالتوك�صي �أ�صبحت ن�صبة معتربة من �خلاليا نخرية بعد 24 �صاعه )�نيكزن )+V+PI(. اخلال�سة: �الأفالتوك�صي مادة 
�صامة للخاليا �لب�رشية �للمفاوية و�صميته تتم عرب �ملوت �خللوي �ملربمج و�لنخر.
مفتاح الكلمات: �الأفالتوك�صي؛ موؤ�رش ك�صف �الأك�صجي؛ �لتنف�س �خللوي؛ �مليتوكوندريا؛ كا�صبي�س؛ �لدم؛ �خلاليا �للمفاوية.
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Advances in Knowledge
- Aflatoxin B1 (AFB1) is a potent immunosuppressant.
- AFB1 induces apoptosis and necrosis in human lymphocytes.
- AFB1 inhibits lymphocyte respiration (mitochondrial oxygen consumption).
Application to Patient Care
- The cytotoxicities of aflatoxin in humans include immunosuppression, mediated by lymphocyte apoptosis and necrosis. 
- Public awareness of the potential immunotoxicity of aflatoxins is needed.
- Effective health regulations are required to minimise the exposure to aflatoxins, especially in immunocompromised hosts.
Aflatoxin B1 (AFB1) is a mycotoxin commonly found in food contaminated by organisms, such as Aspergillus flavus.1,2 
Exposure to AFB1 is linked to several human 
diseases, including hepatocellular carcinoma,3,4 
mutagenesis,5 immunosuppression,6–8 impaired 
infant growth,9–12 and adverse birth outcomes.12,13 
Synergistic interactions with hepatitis B and 
human immunodeficiency viruses have also been 
reported.14,15
The toxin is activated by hepatic cytochrome 
P450 3A4, and its active form (AFB1-exo-8,9- 
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epoxide) rapidly reacts with cellular 
deoxyribonucleic acid (DNA) and proteins.16,17 
Most of the information regarding its immuno-
toxicity has been derived from animal studies.18–20 
The exposure of young children to dietary aflatoxin 
and its toxic effects on human lymphocytes are also 
well established,14,21–24 including the inhibition of 
lymphocyte respiration.25
The term apoptosis describes the caspase- (or 
apoptosome)-mediated cytotoxic processes that 
cause mitochondrial dysfunction, membrane 
damage and DNA fragmentation.26 The apoptotic 
pathways that are independent of apoptosomes are 
also known.27 This study explores the mechanisms 
(biomarkers) of the toxic effects of AFB1 in human 
lymphocytes.
Methods
This study was carried out from November 2008 to 
June 2012. The PBMC were isolated from the whole 
blood of 7 healthy adult volunteers as previously 
described.28 The Institutional Review Board for the 
protection of human subjects of the United Arab 
Emirates University approved the collection of blood 
from the healthy volunteers. Informed consent was 
obtained from the participating volunteers.
The reagents and solutions used were 
as follows. The Pd(II) complex of meso- 
tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin 
([Pd phosphor] at molecular weight [Mr]~1300) 
was purchased from Porphyrin Products 
(Frontier Scientific, Inc., Logan, Utah, USA). 
The dactinomycin was purchased from 
Merck & Co., Inc. (Whitehouse Station, New 
Jersey, USA). The benzyloxy-carbonyl-val-ala-
DL-asp-fluoromethylketone (zVAD-fmk) was a 
Calbiochem® product (EMD Millipore, Billerica, 
Massachusetts, USA). The N-acetyl-asp-glu-val-
asp-7-amino-4-methylcoumarin (Ac-DEVD-AMC) 
was purchased from Alexis Biochemicals (Enzo 
Life Sciences, Inc., Farmingdale, New York, USA). 
The AFB1 (produced by Aspergillus flavus), glucose 
oxidase, D(+)-glucose and remaining reagents were 
from Sigma-Aldrich Co. (St. Louis, Missouri, USA).
The Pd phosphor (at 2.5 mg/mL and 2.0 mM), 
glucose oxidase (at 10 mg/mL) and sodium cyanide 
(at 1.0 M) solutions were prepared in distilled 
water (dH2O) and stored at -20 °C. The phosphate 
buffered saline (PBS) solution was made daily. 
The AFB1, dactinomycin, zVAD-fmk (at 2.14 mM) 
and Ac-DEVD-AMC (at 7.4 mM) solutions were 
prepared and stored as previously described.29–31
Oxygen detection was based on the principle 
described previously,32 and the phosphorescence 
oxygen (O2) analyser used as reported 
elsewhere.33–36 For the fluorescence-activated cell 
sorting (FACS) analysis, an aliquot of 106 of PBMC 
for each subject were cultured with 0, 5, 10, 50 or 
165 µM of AFB1. The cells were harvested after 
2, 16, and 24 hours, and analysed as previously 
described.37 The AFB1 was prepared and measured 
as described.38
The reaction mixtures contained 1.5 x 106 
cells in PBS, 10 mM of glucose and 68 µM of Ac-
DEVD-AMC, with and without zVAD-fmk (at 20 
µM). The mixtures were incubated at 37 °C in glass 
vials (in the dark with continuous agitation) for two 
hours, with and without AFB1 or dactinomycin. 
The suspensions were then diluted with 1.0 mL 
of ice-cold PBS-glucose, sonicated for 60 secs and 
passed through 23-G needles. The supernatants 
were collected by centrifugation (12,300 x g for 
10 mins) and separated on high-performance 
liquid chromatography (HPLC) as described.37 
The released 7-amino-4-methylcoumarin (AMC) 
moiety (peak retention time of ~8.7 mins) was 
detected by fluorescence. A control reaction mixture 
containing PBS-glucose, 68 µM of Ac-DEVD-AMC 
and 5 µl of dimethyl sulfoxide (DMSO) (the vehicle 
for zVAD-fmk) without added cells was monitored 
periodically at 37 °C for the spontaneous release of 
AMC moieties; in these control reactions, the AMC 
peak areas at 0.5, 1, 2 and 3 hours were negligible.
The HPLC analysis of the released AMC 
moieties was done on a Waters Corporation 
(Milford, Massachusetts, USA) reversed-phase 
HPLC system (excitation wavelength of 380 nm 
and emission wavelength of 460 nm). Solvent A was 
acetonitrile (CH3CN) and water (H2O) at a ratio of 
1:3 and solvent B was dH2O. The column, a 4.6 x 
250 mm Ultrasphere® ion pair column (Beckman 
Coulter, Inc., Brea, California, USA), was operated 
at 25 °C at 1.0 mL/min (0.5 mL/min of each pump). 
The run time was 15 mins and the injection volume 
was 20 µL.37
Results
The cellular respiration results were as follows. The 
Suleiman Al-Hammadi, Farida Marzouqi, Aysha Al-Mansouri, Allen Shahin, Mariam Al-Shamsi, Eric Mensah-Brown and 
Abdul-Kader Souid
Clinical and Basic Research | e67
representative O2 consumption runs are shown in 
Figure 1 and 2. In Figure 1, the PBMC (2.5 x 107 cells/
mL) were incubated with 12 µL/mL of DMSO or 25 
µM of AFB1.  At t = 154 mins, 1.0 mL of each mixture 
was simultaneously placed in the instruments for 
the O2 measurements. The respiration rate, zero-
order rate (constant for cellular mitochondrial O2 
consumption (k) in µM O2 min
-1) for untreated 
cells was 3.6 and 1.2 for AFB1-treated cells (67% 
inhibition). In Figure 2, the PBMC (107 cells/mL) 
were incubated with 1.2 µL/mL of DMSO or 2.5 µM 
of AFB1.  At t = 95 mins, 1.0 mL of each mixture was 
simultaneously placed in the instruments for the O2 
measurements. The k values were 1.6 and 1.3 µM of 
O2/min, respectively (19% inhibition).
In four separate experiments, the values of k 
for untreated lymphocytes were 2.2 ± 1.1 µM O2 
min-1 per 107 cells. The corresponding values for 
lymphocytes treated with AFB1 (cells exposed to 
2.5–75 µM of AFB1 for 60–154 mins) were 1.3 ± 0.6 
µM O2 min
-1 per 107 cells; the inhibition was dose-
dependent and ranged from 19–67%.
The caspase activity was monitored after 
incubation for two hours at 37 °C with 100 µM 
of AFB1 (which was added as a powder), with and 
without 20 µM of zVAD-fmk, using the caspase-3 
substrate analogue Ac-DEVD-AMC. Caspase-3 
cleaved Ac-DEVD-AMC, releasing the fluorogenic 
 
Figure 1: The AFB1 (25 µM in DMSO) inhibited the 
PBMC respiration. The PBMC (2.5 x 107 cells/mL in 
PBS-glucose, 3 µM of Pd phosphor and 0.5% of fat-
free albumin) were incubated at 37 °C with 12 µL/
mL of DMSO or 25 µM of AFB1 (in DMSO). Min zero 
corresponded to the addition of AFB1.  At t = 154 mins, 
1.0 mL of each mixture was simultaneously placed in the 
phosphorescence O2 analysers for O2 measurements at 
37 °C. The rates of respiration (k) were calculated from 
the best fit curves. The additions of 5.0 mM of NaCN 
and 50 µg/mL of glucose oxidase are shown.
O2 = oxygen; DMSO = dimethyl sulfoxide; k = zero-order rate 
constant for cellular mitochondrial O2 consumption; R
2 = regression 
coefficient; NaCN = sodium cyanide; AFB1 = aflatoxin B1 ; PBMC 
= human peripheral blood mononuclear cells; PBS = phosphate 
buffered saline; Pd phosphor = Pd(II) complex of meso-tetra-(4-
sulfonatophenyl)-tetrabenzoporphyrin.
 
Figure 2 A & B: The AFB1 (2.5 µM in DMSO) inhibited the PBMC respiration. The PBMC (10
7 cells/mL in PBS-glucose, 
3 µM of Pd phosphor and 0.5% of fat-free albumin) were incubated at 37 °C with 1.2 µL/mL of DMSO (A) or 2.5 µM of 
AFB1 (B). Min zero corresponded to the addition of the AFB1.  At t = 95 mins, 1.0 mL of each mixture was simultaneously 
placed in the phosphorescence O2 analysers for O2 measurements at 37 °C. The rates of respiration (k) were calculated 
from the best-fit curves. The additions of 5.0 mM of NaCN and 50 µg/mL of glucose oxidase are shown.
O2 = oxygen; k = zero-order rate constant for cellular mitochondrial O2 consumption; R
2 = regression coefficient; NaCN = sodium cyanide; AFB1 = 
aflatoxin B1; DMSO = dimethyl sulfoxide; PBMC = the human peripheral blood mononuclear cells; PBS = phosphate buffered saline; Pd phosphor 
= Pd(II) complex of meso-tetra-(4-sulfonatophenyl)-tetrabenzoporphyrin.
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moiety AMC. After cell disruption, the AMC was 
separated on HPLC and detected by fluorescence. 
For untreated cells [Figure 3A], the AMC peak area 
(in arbitrary units) was 273,367 and abolished by 
zVAD-fmk. For cells treated with AFB1 alone [Figure 
3B], the AMC peak area was 32,347,746 (118-fold 
higher). For cells treated with AFB1 and zVAD-fmk 
[Figure 3B], the AMC peak area was 3,522,589 (89% 
inhibition). Similar results were obtained in two 
additional experiments. For comparison, the cells 
were also treated with 20 µM of dactinomycin, 
which is well known to activate caspases. The AMC 
peak area in the presence of dactinomycin alone 
was 54,679,510; in the presence of dactinomycin 
and zVAD-fmk, the peak area was 4,561,062 (92% 
inhibition) [Figure 3C].
The caspase activation was monitored as a 
function of the time of incubation with AFB1. Three 
conditions were tested: untreated cells, cells treated 
with 100 µM of AFB1 alone and cells treated with 
100 µM of AFB1 and 20 µM of zVAD-fmk. The Ac-
DEVD-AMC cleavage was monitored at 15, 30, 60 
and 120 mins after treatment. The AMC moiety 
appeared only after two hours of incubation with 
AFB1; zVAD-fmk blocked ~94% of the AMC peak 
area. This profile of caspase activation was similar 
to that described for dactinomycin and doxorubicin 
in human immortalised T-lymphocytes.28,29
The induction of the lymphocyte apoptosis by 
AFB1 was monitored by flow cytometry, using the 
cell membrane’s permeability to propidium iodide 
(PI) and the phosphatidylserine exposure. There 
were 10 independent experiments performed, and 
the results of these are summarised in Figure 4. The 
PBMC were isolated from the blood of 7 healthy 
volunteers and exposed to 0, 5, 10 or 50 µM of AFB1. 
The FACS analysis was performed at 2, 16 and 24 
hours. With the total number of mononuclear 
cells isolated at 2.5 x 106, the number of Annexin 
V-positive cells increased with incubation time; 
this increase was statistically significant (P <0.05) 
after 16 hours of incubation for each concentration. 
Although the difference in the effect of 5 µM and 
10 µM was not significant (P = 0.082), the increase 
in the number of apoptotic cells after treatment 
with 50 µM was significant [Figure 4 A and B]. It 
is noteworthy that 50 µM of AFB1 also produced 
a significant number of necrotic cells (annexin 
V-positive and PI-positive), which became more 
evident at 24 hours [Figure 4C].
Thus, the results of this study show that AFB1 
inhibits cyanide-sensitive cellular respiration. The 
toxin also induces apoptosis and necrosis.
Discussion
The phosphorescence O2 analyzer, caspase assay 
and flow cytometry were used here to confirm the 
toxic effects of AFB1 on human lymphocytes.
25 The 
results show that AFB1 impairs human lymphocyte 
 
Figure 3 A‒C: The intracellular caspase activation by AFB1 and dactinomycin. Each mixture (final volume of 0.5 mL) 
contained 1.5 x 106 cells in PBS-glucose and 68 µM of Ac-DEVD-AMC, with and without 20 µM of zVAD-fmk. The 
suspensions were incubated at 37 °C for two hours without addition (A), with the addition of 100 µM of AFB1 (B) or 
with the addition of 20 µM of dactinomycin (C). At the end of the incubation period, the cells were disrupted and their 
supernatants were separated via HPLC. The AMC moiety was monitored by fluorescence. The retention time for the Ac-
DEVD-AMC was ~2.4 mins and ~8.7 mins for the AMC.
PBMC = the human peripheral blood mononuclear cells; zVAD-fmk = benzyloxy-carbonyl-val-ala-DL-asp-fluoromethylketone; AMC = 
7-amino-4-methylcoumarin; AFB1 = aflatoxin B1 ; PBS = phosphate buffered saline; Ac-DEVD-AMC = N-acetyl- asp-glu-val-asp-7-amino-4-
methylcoumarin; HPLC = high-performance liquid chromatography.
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mitochondrial function [Figure 1 and 2] and 
activates intracellular caspases [Figure 3]. The AFB1 
also produces lymphocyte apoptosis and necrosis 
[Figure 4]. The caspases become active in the cells 
within two hours of the AFB1 addition [Figure 3]. 
This period is similar to that needed to inhibit 
cellular respiration [Figure 1 and 2].
In one study, 32 µM of AFB1 had a minimum 
effect on human lymphocyte proliferation following 
phytohaemagglutinin-P stimulation.39 However, an 
earlier study on human lymphocytes showed less 
lymphocyte proliferation in the presence of 16 µM 
of AFB1.
40 The AFB1 also inhibited concanavalin 
A-promoted lymphocyte proliferation (50% 
inhibition at 60 nM).20 Moreover, AFB1 was shown 
to induce apoptosis in human lymphocytes.41,42
The concentrations of AFB1 used here were 
relatively high, especially since the average human 
exposure in Eastern China is only ~0.5 mmol/day.3 
It is important, however, to emphasise that the 
stability of AFB1 in solutions is poor and the bulk of 
the toxin is deactivated by the rapid reaction with 
H2O.
43 Thus, the data presented here mainly point 
to the potential immunotoxicity of AFB1.
The caspase activity reaction described was 
previously calibrated using recombinant human 
caspase-3.28 The AMC was expressed as peak 
areas (in arbitrary units) per number of cells. The 
reactions were conducted in the presence and 
absence of the pan-caspase inhibitor zVAD-fmk. It 
is of note that the substrate Ac-DEVD-AMC can 
be cleaved by several caspases, including caspase-3 
(turnover number [kcat]/ Michaelis constant [Km] 
= 218,000 s-1); caspase-7 (kcat/Km = 37,000 s-1); 
caspase-1/interleukin-1 converting enzyme (kcat/Km 
= 30,000 s-1); caspase-6 (kcat/Km = 2,000 s-1), and 
caspase-4 (kcat/Km = 1,800 s-1).
44
 
Figure 4 A–C: The flow cytometry analysis of the apoptosis. A: The percentages of the Annexin V-positive cells; data 
are representative of samples from 7 healthy individuals. B: The quantification of the FACS analysis of the apoptotic 
(Annexin V-positive) cells from 7 healthy donors stained with PI and Annexin V at 24 hours (horizontal lines), 16 hours 
(vertical lines) and two hours (no lines). C: The quantification of the FACS analysis of the necrotic (Annexin V-positive 
and PI-positive) cells after treatment with 50 µM of AFB1. 
PI = propidium iodide; FACS = fluorescence-activated cell sorting; AFB1 = aflatoxin B1 .
*P <0.05; **P <0.005.
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Conclusion
Human lymphocytes exposed in vitro to AFB1 
exhibit impairments in cellular respiration, caspase 
activation and necrosis. The results underscore the 
immunosuppressive activity of aflatoxins in humans 
exposed to this natural fungal toxicant.
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